Yeast: bridging the gap between phenotypic and biochemical assays for high-throughput screening

Denny, Paul W.

Abstract

Introduction: Both in vitro biochemical and phenotypic assay platforms have clear limitations in high throughput screening (HTS) for drug discovery. The use of genetically tractable model yeast as a vehicle for target-based HTS overcomes many of these by allowing the identification of on-target compounds that function within a eukaryotic cellular context. Areas covered: In this special report, the use of yeast-based assays in HTS is discussed with reference to the various platforms that have been utilized over the past 20 years. The specific issues considered are the necessity to employ counter and secondary screening approaches to ensure the on-target activity of hits, and the recent developments in detection systems that have facilitated miniaturization and ultra-HTS. Expert opinion: It is difficult at present to predict the future. That being said, the demonstrable possibilities of optimizing yeast-based HTS, coupled with the demonstration of utility in an industrial setting, shows that these platforms have the potential to bridge the gap between phenotypic and biochemical assays for HTS.

Citation

Denny, P. W. (2018). Yeast: bridging the gap between phenotypic and biochemical assays for high-throughput screening. Expert Opinion on Drug Discovery, 13(12), 1153-1160. https://doi.org/10.1080/17460441.2018.1534826

• Journal Article Type: Article
• Acceptance Date: Oct 8, 2018
• Online Publication Date: Oct 16, 2018
• Publication Date: Oct 16, 2018
• Deposit Date: Oct 17, 2018
• Publicly Available Date: Oct 16, 2019
• Journal: Expert Opinion on Drug Discovery
• Print ISSN: 1746-0441
• Electronic ISSN: 1746-045X
• Publisher: Taylor and Francis Group
• Peer Reviewed: Peer Reviewed
• Volume: 13
• Issue: 12
• Pages: 1153-1160
• DOI: https://doi.org/10.1080/17460441.2018.1534826
• Public URL: https://durham-repository.worktribe.com/output/1316230